Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Treib, J.
Right arrow Articles by Woessner, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Treib, J.
Right arrow Articles by Woessner, R.
NEUROLOGY 1998;51:1489-1491
© 1998 American Academy of Neurology

Clinical and serologic follow-up in patients with neuroborreliosis

J. Treib, MD, A. Fernandez, MD, A. Haass, MD, M. T. Grauer, G. Holzer, PhD and R. Woessner

From the Department of Neurology, University of the Saarland, Homburg, Germany.

Address correspondence and reprint requests to Priv.-Doz. Dr. Johannes Treib, Department of Neurology, University of the Saarland, Kirrbergerstrasse, D-66421 Homburg, Germany.

The authors performed a clinical and serologic follow-up study after 4.2 ± 1.2 years in 44 patients with clinical signs of neuroborreliosis and specific intrathecal antibody production. All patients had been treated with ceftriaxone 2 g/day for 10 days. Although neurologic deficits decreased significantly, more than half the patients had unspecific complaints resembling a chronic fatigue syndrome and showed persisting positive immunoglobulin M serum titers for Borrelia in the Western blot analysis.

Supported by Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany.

Received April 14, 1998. Accepted in final form June 27, 1998.




This article has been cited by other articles:


Home page
 NeurologyHome page
J. J. Halperin, E. D. Shapiro, E. Logigian, A. L. Belman, L. Dotevall, G. P. Wormser, L. Krupp, G. Gronseth, and C. T. Bever Jr
Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurology, July 3, 2007; 69(1): 91 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Widhe, B. H. Skogman, S. Jarefors, M. Eknefelt, G. Enestrom, M. Nordwall, C. Ekerfelt, S. Croner, S. Bergstrom, P. Forsberg, et al.
Up-regulation of Borrelia-specific IL-4- and IFN-{gamma}-secreting cells in cerebrospinal fluid from children with Lyme neuroborreliosis
Int. Immunol., October 1, 2005; 17(10): 1283 - 1291.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. Eskow, R.-V. S. Rao, and E. Mordechai
Concurrent Infection of the Central Nervous System by Borrelia burgdorferi and Bartonella henselae: Evidence for a Novel Tick-borne Disease Complex
Arch Neurol, September 1, 2001; 58(9): 1357 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Primavera, P. Gazzola, A. F. De Maria, J. Treib, M. T. Grauer, R. Woessner, and A. Haass
Neuropsychological deficits in neuroborreliosis
Neurology, September 1, 1999; 53(4): 895 - 895.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by AAN Enterprises, Inc.